RxDoctor Payments DataLook up a doctor →

Ryan Koch, DO

Medical Oncology · Searcy, ARNPI 1386684603

Payments from drug & device makers

$15,296in general payments, 2019–2025

Across 891 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Merck$974
  • Incyte Corporation$732
  • Seagen Inc.$596
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$14,57095%
  • Education$7265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis82$1,305
AstraZeneca(2 entities)62$1,189
Pfizer73$1,063
Merck63$974
Incyte Corporation35$732
Seagen Inc.33$596
GSK31$555
Genentech USA, Inc.36$531
Lilly USA, LLC33$522
Daiichi Sankyo Inc.30$511
Johnson & Johnson(2 entities)28$482
Bristol Myers Squibb26$479
Sanofi28$465
E.r. Squibb & Sons, L.L.C.33$454
Myriad Genetic Laboratories, Inc.7$451
AbbVie22$398
Amgen23$367
Eisai Inc.17$269
Foundation Medicine, Inc.7$248
Gilead(2 entities)15$243
Bayer14$227
Exelixis Inc.14$224
Epizyme, Inc.11$181
Array Biopharma Inc12$178
Regeneron Healthcare Solutions, Inc.10$178
Pharmaessentia USA Corporation9$153
Beigene USA, Inc.9$151
Ipsen Biopharmaceuticals, Inc9$151
Pharmacyclics LLC, An Abbvie Company9$150
Astellas Pharma US Inc8$137
EMD Serono, Inc.7$115
AVEO Pharmaceuticals, Inc.6$113
Mirati Therapeutics, Inc.6$111
Takeda Pharmaceuticals U.S.A., Inc.6$96
Tolmar Pharmaceuticals, Inc.5$92
Boehringer Ingelheim5$91
Pharmacosmos Therapeutics Inc.6$87
Puma Biotechnology, Inc.5$84
G1 Therapeutics, Inc.5$70
Dendreon Pharmaceuticals LLC4$68
Dova Pharmaceuticals4$63
Iovance Biotherapeutics, Inc.3$62
Adaptive Biotechnologies Corporation3$57
Karyopharm Therapeutics Inc.3$49
Clovis Oncology, Inc.3$49
Sobi, Inc3$49
Beone Medicines USA, Inc.2$46
Tersera Therapeutics LLC2$43
CTI Biopharma Corp.2$42
Fennec Pharmaceuticals, Inc.3$42
Teva Pharmaceuticals USA, Inc.3$37
Servier Pharmaceuticals LLC2$32
Jazz Pharmaceuticals Inc.2$31
Acceleron Pharma, Inc.2$30
Kyowa Kirin, Inc.1$28
Taiho Oncology, Inc.2$27
Immunogen, Inc.1$22
Tesaro, Inc.1$20
Mylan Institutional Inc.1$16
ADC Therapeutics America, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,296 in reported general payments places this provider in the 60th percentile of 20 medical oncology providers in Arkansas.

See all medical oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$166,035
Medicare patients
405
Services billed
1,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib25$277,041
ImbruvicaIbrutinib22$256,593
BrukinsaZanubrutinib15$224,455
BesremiRopeginterferon Alfa-2b-Njft12$205,087
XareltoRivaroxaban74$44,273
EliquisApixaban59$38,805
CreonLipase/Protease/Amylase15$6,064
Anastrozole166$3,450
Letrozole166$2,395
Exemestane13$2,355
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$1,627
Potassium Chloride47$1,438
Oxycodone Hcl46$1,345
Tamoxifen Citrate52$903
Fluconazole28$714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio, Olanzapine$522$277,12438 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$150$256,59322 claims
Beigene USA, Inc.Brukinsa$151$224,45515 claims
Pharmaessentia USA CorporationBesremi$153$205,08712 claims
Johnson & JohnsonXarelto$482$44,27374 claims
PfizerEliquis$1,063$38,80559 claims
AbbVieCreon$398$6,06415 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$37$23725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 20 medical oncology providers in Arkansas.

Other medical oncology in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →